Adaptimmune Therapeutics rises on promising cancer therapy data

Adaptimmune Therapeutics

09/09/2022 15:16

** Shares of cancer therapies developer Adaptimmune
Therapeutics PLC  ADAP.O  rise 2% to $2.08 in early trade
    ** Reports promising data in early-stage trial for all tumor
types
    ** Says 44% of patients with late-stage ovarian, urothelial,
and head & neck cancers, who were earlier treated with existing
drugs, responded to experimental therapy ADP-A2M4CD8
 urn:newsml:reuters.com:*:nFWN30G0JZ
    ** Plans to start mid-stage trial later this year
    ** Despite session's gain, stock down 45% YTD

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))